Kisqali (ribociclib) approved for additional indications in HR+/HER2- advanced breast cancer

Last updated: 01 November 2019

You can legally access new medicines, even if they are not approved in your country.

Learn how

Kisqali (ribociclib) has been approved by the US Food and Drug Administration (FDA) for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. Kisqali is now the only CDK4/6 inhibitor indicated for use with an aromatase inhibitor for the treatment of pre-, peri- or postmenopausal women in the US, and also is indicated for use in combination with fulvestrant as both first- or second-line therapy in postmenopausal women. FDA reviewed this supplemental New Drug Application (sNDA) under its Real-Time Oncology Review and Assessment Aid pilot programs and approved the application in less than one month after submission.

Read the full article here.

Source: Drugs.com